| Objective:Hypopharyngeal squamous cell carcinoma（HSCC）is one of the more common types of head and neck squamous cell carcinoma（HNSCC）in northeastern China.HSCC is insidious,and most patients are already in the middle to late stage and have a poor prognosis at the time of diagnosis.Unfortunately,the pathogenesis of HSCC is not well understood at this stage,so it is important to identify potential molecular markers for clinical diagnosis and new therapeutic targets to improve the prognosis of HSCC patients.Monocarboxylate transporter 1（MCT1）is a transmembrane transporter protein encoded by the Solute carrier family 16 member 1（SLC16A1）gene,which is involved in lactate transport during glycolysis,and is overexpressed in malignant tumors such as kidney cancer,lung cancer and breast cancer.Its overexpression in malignant tumors such as kidney cancer,lung cancer and breast cancer is associated with the proliferation,metastasis and prognosis of tumor cells.Recent studies have found that high expression of MCT1 in HNSCC is associated with tumor proliferation and metastasis.However,studies on the expression of MCT1 in HSCC have not been reported.Therefore,this study aims to investigate the expression of MCT1 in HSCC,to investigate its potential diagnostic markers and new therapeutic targets for HSCC,and to provide a theoretical basis for the study of HSCC pathogenesis.Methods:1.HNSCC-related genes were searched in the literature and bioinformatic analysis was performed using gene expression databases to analyze their correlation with clinical features of HNSCC;HSCC-related genes were screened,target genes were anchored and further gene enrichment analysis was performed,and protein protein interaction networks were constructed.2.TMT proteomics quantitative analysis was applied to screen differentially expressed proteins in tumor tissues and paraneoplastic tissues of 7 HSCC patients to clarify the expression of MCT1 in HSCC.3.The expression of MCT1 in tumor tissues and paraneoplastic tissues of 9HSCC patients were analyzed semi-quantitatively using immunohistochemistry;the expression of MCT1 in tumor tissues and paraneoplastic tissues of 10 HSCC patients were quantified using Western blot,and the differential expression of MCT1 was verified at the tissue level.4.The differential expression of MCT1 was verified at the cellular level by quantitative analysis of MCT1 expression in cultured human pharyngeal squamous carcinoma cell line（FaDu cell line）and human immortalized epidermal cell line（HaCat cell line）by Western blot.Results:1.Bioinformatic analysis showed that SLC16A1 gene was significantly highly expressed in HNSCC tumor tissues;SLC16A1 expression was significantly correlated with patients’ pathological grade（degree of differentiation）and Human papillomavirus（HPV）expression,and negatively correlated with Overall survival（OS）.2.Bioinformatic analysis showed that SLC16A1 gene expression was upregulated in HSCC tissues,and gene enrichment analysis revealed that the upregulation of SLC16A1 gene expression might be closely related to the extracellular matrix,PI3K/Akt signaling pathway and NF-κB signaling pathway.3.TMT proteomics quantitative analysis showed that the expression level of MCT1 was significantly higher in HSCC tumor tissues compared with paraneoplastic tissues.4.Immunohistochemistry and Western blot results of HSCC tumor tissues and paraneoplastic tissues both showed that the expression of MCT1 was significantly higher in HSCC tumor tissues than in paraneoplastic tissues.5.Western blot results of FaDu cell line and HaCat cell line showed that the expression of MCT1 was significantly higher in FaDu cell line than in HaCat cell line.Conclusion:1.The high expression of SLC16A1 gene in HNSCC tissues correlated with the pathological grade（degree of differentiation）and HPV expression of HNSCC tumors,and negatively correlated with OS.2.MCT1 is highly expressed in HSCC tumor tissues.3.MCT1 is highly expressed in the FaDu cell line. |
PDF Full Text Request